Rare Diseases Report 2022

The broad and challenging – but promising – landscape of peripheral neuropathy


 

Therapeutic options

There are no FDA-approved treatments for CSPN, as most treatments are geared toward neuropathic pain management, rehabilitation, and supportive care.68 Due to a lack of research and data regarding these types of peripheral neuropathies, various studies suggest different first-line therapies. For example, anticonvulsants (pregabalin, gabapentin), antidepressants (duloxetine), and opioid-like compounds (tramadol) are all threapy options to treat DPN.3

Adequate data are lacking to support the efficacy of immunosuppressive therapy in CSPN.

Pages

Recommended Reading

FDA okays spesolimab, first treatment for generalized pustular psoriasis
MDedge Internal Medicine
ILD on the rise: Doctors offer tips for diagnosing deadly disease
MDedge Internal Medicine
A farewell to arms? Drug approvals based on single-arm trials can be flawed
MDedge Internal Medicine
Uncombable hair syndrome: One gene, variants responsible for many cases
MDedge Internal Medicine
Increasing primary care doctors’ knowledge of IPF could speed up diagnoses, suggests white paper
MDedge Internal Medicine
ALS drug gets FDA panel thumbs-up after rare second look
MDedge Internal Medicine
Myasthenia gravis: Finding strength in treatment options
MDedge Internal Medicine
Cancer as a full contact sport
MDedge Internal Medicine
IVIG proves effective for dermatomyositis in phase 3 trial
MDedge Internal Medicine
Combination of energy-based treatments found to improve Becker’s nevi
MDedge Internal Medicine